Stanford University
Showing 1-8 of 8 Results
-
Laura Attardi
Catharine and Howard Avery Professor of the School of Medicine and Professor of Genetics
Current Research and Scholarly InterestsOur research is aimed at defining the pathways of p53-mediated apoptosis and tumor suppression, using a combination of biochemical, cell biological, and mouse genetic approaches. Our strategy is to start by generating hypotheses about p53 mechanisms of action using primary mouse embryo fibroblasts (MEFs), and then to test them using gene targeting technology in the mouse.
-
Richard Frock
Assistant Professor of Radiation Oncology (Radiation and Cancer Biology)
Current Research and Scholarly InterestsWe are a functional genomics laboratory interested in elucidating mechanisms of DNA repair pathway choice and genome instability. We use genome-wide repair fate maps of targeted DNA double strand breaks (DSBs) to develop pathway-specific models and combinatorial therapies. Our expertise overlaps many different fields including: genome editing, ionizing radiation, cancer therapeutics, V(D)J and IgH class switch recombination, repair during transcription and replication, and meiosis.
-
Amato J. Giaccia
Jack, Lulu and Sam Willson Professor, Professor of Radiation Oncology, Emeritus
Current Research and Scholarly InterestsDuring the last five years, we have identified several small molecules that kill VHL deficient renal cancer cells through a synthetic lethal screening approach. Another major interest of my laboratory is in identifying hypoxia-induced genes involved in invasion and metastases. We are also investigating how hypoxia regulates gene expression epigenetically.
-
Mohammad Shahrokh Esfahani
Assistant Professor of Radiation Oncology (Radiation and Cancer Biology)
Current Research and Scholarly InterestsMy laboratory develops computational and statistical methods to extract clinically actionable information from cancer genomic data, particularly circulating cell-free DNA. We combine cancer genomics, liquid biopsy, and machine learning to improve early cancer detection, characterize minimal residual disease, monitor treatment response, and understand therapeutic resistance across solid tumors and hematologic malignancies.
